Welcome to our dedicated page for Fibrobiologics news (Ticker: FBLG), a resource for investors and traders seeking the latest updates and insights on Fibrobiologics stock.
FibroBiologics, Inc. develops fibroblast-based and fibroblast-derived therapies for chronic diseases and regenerative medicine applications. News about FBLG centers on its clinical-stage cell-therapy platform, including CYWC628 for diabetic foot ulcers, CYPS317 for psoriasis, CYMS101 for multiple sclerosis, and related programs in wound healing, disc degeneration, orthopedics, cancer, immune aging, and pulmonary inflammatory conditions.
Company updates commonly cover clinical-trial preparation and drug-product manufacturing, preclinical data from fibroblast spheroids and thymic organoid research, scientific meeting presentations, shareholder communications, quarterly financial results, Nasdaq listing compliance, and capital-planning actions that support development of its fibroblast technology pipeline.
FibroBiologics (Nasdaq:FBLG) reported preclinical data for its psoriasis program CYPS317, using human dermal fibroblast (HDF) spheroids, presented at the 2026 Society for Investigative Dermatology meeting.
In psoriasis animal models, HDF spheroids reduced disease severity, prevented relapse, improved systemic safety versus single-cell HDFs, and showed targeted immunomodulation across key inflammatory pathways.
FibroBiologics (Nasdaq:FBLG) filed a new provisional patent application with the USPTO for oral fibroblast and fibroblast-derived therapeutics. The platform targets delivery to the gastrointestinal tract using encapsulation materials, hydrogels, nanoparticles, protective layers, and pH-sensitive coatings to preserve viability and enable targeted release.
The application covers whole fibroblast cells, spheroids, extracellular vesicles, fragments, conditioned media, and genetically modified variants, with potential use in chronic GI disorders such as inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, peptic ulcer disease, celiac disease, gastritis, and gastrointestinal cancers.
FibroBiologics (Nasdaq:FBLG) is expanding its fibroblast-based therapeutic platform to target Hantavirus pulmonary syndrome (HPS), building on preclinical work in acute respiratory distress syndrome (ARDS). HPS has >35–40% mortality and no approved antivirals.
The company is testing fibroblasts in Hantavirus models, focusing on inflammatory cytokine modulation, endothelial permeability, and tissue repair, and plans exploratory regulatory discussions toward potential clinical evaluation.
FibroBiologics (Nasdaq: FBLG) announced initiation of its clinical trial for lead program CYWC628, an investigational fibroblast-based therapy for diabetic foot ulcers. The company completed initial site activation and plans patient enrollment in Q2 2026 with topline data expected by end of 2026.
Management says its capital plan funds operations through the topline readout and highlights ongoing preclinical programs in multiple sclerosis, psoriasis, and an artificial thymus organoid platform.
FibroBiologics (Nasdaq: FBLG) reported preclinical burn-wound data on May 4, 2026 showing topical human dermal fibroblast (HDF) spheroids produced visible anti-inflammatory effects by day 8 and altered wound biomarkers.
Key findings include reduced inflammatory appearance across strains and sexes, ~3-fold lower IL1B and ~4-fold higher IL10 (p<0.01), and downward trends in collagen, ECM turnover, and myofibroblast activation genes.
FibroBiologics (Nasdaq: FBLG) announced on May 4, 2026 the release of the first cGMP batch of its investigational drug product CYWC628 to support a Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs).
The batch was manufactured under cGMP and passed required safety and quality testing, enabling clinical use and positioning the company to begin patient enrollment for safety, tolerability, and preliminary efficacy evaluation.
FibroBiologics (Nasdaq: FBLG) reported Q1 2026 results and a corporate update on April 30, 2026. Key items: completed cGMP manufacture of initial CYWC628 batches, completed site onboarding, positive preclinical data in burn and degenerative disc programs, regained Nasdaq compliance, and raised capital via direct offerings.
Financials: R&D $3.0M, G&A $2.1M, net loss ~$5.0M, cash $1.5M at March 31, 2026; $2.5M net raised after quarter.
FibroBiologics (Nasdaq: FBLG) will present preclinical data for its CYPS317 psoriasis program at the Society for Investigative Dermatology Annual Meeting, May 13–15, 2026, in Chicago. The poster session featuring Chuo Fang, MD, Ph.D., is scheduled for May 15, 2026, 4:30–6:00 p.m. CT in Salons B, C, D; Williford – 3rd Floor.
For more information, attendees can visit FibroBiologics' website, email info@fibrobiologics.com, or follow the company on LinkedIn, YouTube, Facebook, or X.
FibroBiologics (Nasdaq: FBLG) announced Nasdaq has confirmed the company meets all applicable continued-listing criteria, including the $2.5 million stockholders' equity and the $1.00 bid price requirements. The company resolved its compliance issues but will remain under one-year monitoring for both metrics.
FibroBiologics is a clinical-stage biotech with 270+ patents issued and pending; its common stock will continue trading on Nasdaq under FBLG.
FibroBiologics (Nasdaq: FBLG) presented preclinical data on April 10, 2026 showing a proprietary thymic organoid platform that restored multiple thymic functions in immunodeficient mice.
Organoids generated diverse, functional T cell lineages, maintained key thymic gene expression, were cryopreservable and injectable, and slowed tumor growth in a melanoma model.